Observational Evidence for Buprenorphine's Impact on Posttraumatic Stress Symptoms in Veterans With Chronic Pain and Opioid Use Disorder.

摘要: Objective Posttraumatic stress disorder (PTSD), chronic pain, and substance use disorders are prevalent co-occurring conditions that challenging to treat individually, there is no evidence-based treatment for all 3. Buprenorphine, used opioid a partial nociceptin receptor agonist. In preclinical studies, agonist was shown mitigate PTSD symptoms in acute trauma. We compared buprenorphine other medications its impact on patients with pain and/or disorders. Method assembled retrospective cohort of 382 Iraq Afghanistan veterans US Department Veterans Affairs health care from October 1, 2007, July 29, 2013, ICD-9-CM diagnoses PTSD, time-varying general estimating equation models assess the primary outcome, which change (measured using Checklist Primary Care Screen) among initiated sublingual versus those maintained moderately high-dose therapy. Results Twice as many group (23.7%) therapy (11.7%) experienced improvement (P = .001). Compared group, receiving showed significant after 8 months, increasing up 24 months (incidence rate ratio 1.79; 95% CI, 1.16-2.77; P .009). There were differences longitudinal course ratings between groups. Conclusions This observational study first report an incidental effect improving veterans.